In this Exclusive Interview, Dr. Davidson discusses his thoughts on new drugs and their impact on patient health, such as DKA.
Read More »Use of SGLT-2 inhibitors As Adjunct to Insulin In People with Type 1 Diabetes
Apart from Sotagliflozin’s use in the treatment of people with type 2, SGLT-1 and SGLT-2 inhibitors effects on type 1 currently being explored.
Read More »ADA: Canagliflozin Reduces Risk of Cardiovascular Disease, Hospitalization for Heart Failure; Associated with Renal Protective Effects
CANVAS Program results confirm cardiovascular benefits are SGLT-2 Inhibitor Class effect.
Read More »Exclusive: Dr. Bruce Neal Discusses Canagliflozin’s Potential for Heart Failure Prevention
Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have an exclusive interview from ADA 2017. The CANVAS study’s outcomes were “a positive first step” in proving that canagliflozin can be used for the primary prevention of heart failure in patients with diabetes, but more evidence is needed, according to the study’s lead author, Dr. Bruce Neal.
Read More »Bruce Neal ADA 2017 Pt.1, CANVAS Program and Cardiovascular Event Reduction
Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. In Part 1 of this …
Read More »Bruce Neal ADA 2017 Pt.2 CANVAS Program and Renal Protection
Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. In Part 2 of this exclusive …
Read More »Bruce Neal ADA 2017 Pt.3 CANVAS Program Compared to Other Studies
Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. In Part 3 of this exclusive …
Read More »Bruce Neal ADA 2017 Pt.4 CANVAS Program, What Should be Taken Away
Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. In Part 4 of this exclusive …
Read More »Bruce Neal ADA 2017 Pt.5, FDA SGLT2 Guidelines
Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. In Part 5 of this exclusive …
Read More »Bruce Neal ADA 2017 Pt.6, Adverse Effects for SGLT2
Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. In Part 6 of this exclusive …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.